Best Pet RX IP, Inc.;Professional Compounding Centres of America (PCCA)
发明人:
Simmons, Chris V.,Danny, Carrero
申请号：
AU2016204933
公开号：
AU2016204933A1
申请日:
2016.07.14
申请国别(地区):
AU
年份:
2017
代理人:
摘要：
#$%^&*AU2016204933A120170202.pdf#####ABSTRACT OF THE DISCLOSURE Intralesional injections including poloxamer compounds and anticancer drugs are disclosed. The combination of the poloxamer-based composition with chemotherapeutic agents within the disclosed intralesional injections provides a synergistic effect, thereby allowing lower dosages of the active drugs and enhancing the treatment effectiveness. The disclosed poloxamer-based intralesional injections are employed for treating different types of cancer in humans and other animal species. The disclosed intralesional injections can be used as the sole therapy or in combination with one or more additional therapies, such as, chemotherapy, electrotherapy, immunotherapy and/or radiation therapy. The disclosed intralesional injections can be employed in virotherapy and gene therapy treatments. The disclosed intralesional injections are designed for immediate release or controlled release of the active drugs. The disclosed intralesional injections are employed for local or systemic administration of active drugs.
